Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
M.D. Anderson Cancer Center
City of Hope Medical Center
Mayo Clinic
University of Washington
Mayo Clinic
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
Northwestern University
OHSU Knight Cancer Institute
National Institutes of Health Clinical Center (CC)
Mayo Clinic
McGill University Health Centre/Research Institute of the McGill University Health Centre
University of Washington
University of Kansas Medical Center
University of Washington
Barbara Ann Karmanos Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Fudan University
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
M.D. Anderson Cancer Center
University of Texas Southwestern Medical Center
University of California, San Francisco
University of Kansas Medical Center
Children's Oncology Group
Heidelberg University
National Institutes of Health Clinical Center (CC)